19Reveal Genomics staff joining Hologic
$4.1BHologic revenue in fiscal 2025
27GeneDx abstracts accepted at ASHG 2026
Funding & M&A
Hologic agrees to buy Reveal Genomics
The Barcelona start-up behind the HER2DX breast cancer test joins Hologic's oncology diagnostics, alongside its Breast Cancer Index. Price not disclosed.
Read the full story →Why it matters: small test developers are trading independence for a ready-made sales and reimbursement channel.
Sequencing & Testing
GeneDx plans long-read genome sequencing
Long reads will join its rare disease genome testing to catch structural variants and repeat expansions that short reads can miss. Early access is due by year-end.
Read the full story →Leadership Moves
Oxford Nanopore
Sebastian Kronmueller, formerly head of strategy and ventures at Royal Philips, joins as US-based chief business development officer from 4 January 2027.
Read the full story →Talent Insight
Integration and interpretation are the new hiring bottlenecks
- When a small test developer joins a large group, the hiring moves to integration: market access, reimbursement and specialist sales people who can carry a new assay through an existing channel.
- Long-read and structural-variant testing raises the bar for clinical scientists and variant curators. People who can sign out complex findings will be harder to find than people who can run the instrument.
- For 2027 plans, budget for business development and partnership leaders close to US customers. Platform companies increasingly win on partnerships, not just technology.
Building a team in Genomics & Diagnostics?
Eric Sharma specialises in Genomics & Diagnostics hiring at QP Group. Talk to Eric about the market, salaries or a search.
Eric SharmaThe Sequence · QP Group
eric@qpexec.com
eric@qpexec.com